-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shenzhen Huixin Biomedical Technology Co.
, Ltd.
(hereinafter referred to as "Huixin Biotechnology") announced the completion of tens of millions of yuan in Pre-A round financing
.
This round of financing was led by Weidu Venture Capital, followed by Green River Investment, and the old shareholder Kai Venture Capital made additional investment
in excess of proportion.
This round of financing will be used for the in-depth development and mass production of exosome purification equipment and systems, as well as clinical research and market launch of
exosome diagnosis and therapeutic products.
Founded by renowned scientists and industry experts in the field of exosomes, Huixin Biologics is committed to developing world-leading biotechnologies and products to promote the application
of exosomes in cancer diagnosis and cell therapy.
Its core team has many years of rich experience
in academic research, product development and market development.
Since its establishment, relying on professional technical talents in the industry and cooperative research with a number of scientific research institutions, combined with the team's rich experience in the field of medical device development, Huixin Biotech has launched the world's first non-labeled automatic purification system for exosome isolation and purification - EXODUS®
.
In addition, based on the advanced exosome purification technology platform, Huixin Biotech has also made positive progress
in the development of urological tumor diagnostic kits and large-scale stem cell exosome preparation.
of exosomes in cancer diagnosis and cell therapy.
Yang Yijie, general manager of Huixin Biotechnology, said: "Thanks to the recognition and support of this round of investment institutions, we have optimized, upgraded and mass-produced the company's existing technologies in the past year, and have been recognized
by scientific research users and experts in the exosome industry.
Huixin Biologics will continue to adhere to technological innovation to promote the application
of exosomes in early cancer diagnosis, cell therapy and regenerative medicine.
We will continue to develop a series of products for the urgent needs of the market, provide advanced technical support for the basic research and clinical application of foreign exosomes in China, and make our own contributions
to building an innovative and accessible major disease prevention and treatment ecosystem and the upgrading of the medical and health industry in China.
Weidu Venture Capital, the leading investment institution of this round, said that exosomes have shown great potential in the treatment, diagnosis and medical beauty repair of various complex diseases such as tumors and neurological diseases, and have broad
application prospects.
Huixin Biotech is positioned to solve the bottleneck of exosome applications, and the exosome extraction equipment developed is expected to become a key tool for isolation and purification in the upstream of the exosome industry chain, thereby accelerating the progress of
downstream applications.
The core team members of Huixin Biotech have complex backgrounds and rich experience in exosome academic research, product development and commercialization, and believe that the company will promote the development
of exosome industry in the medical and health fields under the leadership of the founding team.
Weidu Venture Capital will adhere to the belief of "helping entrepreneurs reach the other shore" to accompany the company's growth
.
Angel round investor Kai Venture Capital said: Kai Venture Capital continues to cultivate in the field of precision medicine, exosome detection is an important part of the field of precision diagnosis and treatment, and Kai Venture Capital will continue to pay attention to its technological progress and industrialization opportunities
.
Once the innovative technology developed by Huixin Biotech was published, its unique technical principles and potential huge business opportunities attracted the attention of our team and quickly completed the angel investment
in the company.
We are very pleased to see the rapid growth of Huixin Biotech in the past year, and we are fortunate to witness the many achievements
of EXODUS® technology in the field of exosome isolation and purification.
We look forward to working with Huixin Biologics to go further in the field of exosomes and help Huixin become a leader in
the exosome industry.
"
This round of co-investor Green River Investment said that exosomes have the characteristics of broad-spectrum secretion, targeted delivery, and endocannabinoid diversity, and have great research value and clinical application potential, attracting a lot of scientific research investment and capital attention
.
The research and clinical transformation of exosomes have been pushed to a climax, and the number of participating companies has continued to grow and the scale has continued to expand
.
Huixin Biotech has a team with exosome expertise and rich experience in the field of medical devices, which is expected to help the exosome industry at home and abroad solve the problems of
purification and enrichment, targeted delivery, and drug loading.
Green River Investment firmly believes that "technology creates value, growth increases value", and as an active investor, it will accompany Huixin Biotech to grow
together for a long time.
